Transcatheter arterial chemoembolization (TACE) is a key treatment for patients with primary hepatocellular carcinoma (PHC) who cannot have surgery, with two types: conventional TACE (c-TACE) and drug-eluting bead TACE (DEB-TACE), each having different characteristics that affect their effectiveness.
A study analyzed outcomes of DEB-TACE and c-TACE in PHC patients, using propensity-score matching to ensure balanced comparison, with 86 patients in each group after matching.
Results showed DEB-TACE had better clinical efficacy, with higher objective response and disease control rates, as well as improved liver function post-treatment, indicating it may be a more effective option for treating PHC